- Home
- CTEV vs AVBP Comparison
CTEV vs AVBP Comparison
Compare CTEV & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTEV
- AVBP
- Stock Information
- Founded
- CTEV 1980
- AVBP 2021
- Country
- CTEV United States
- AVBP United States
- Employees
- CTEV N/A
- AVBP N/A
- Industry
- CTEV
- AVBP
- Sector
- CTEV
- AVBP
- Exchange
- CTEV NYSE
- AVBP NYSE
- Market Cap
- CTEV 794.4M
- AVBP 862.8M
- IPO Year
- CTEV N/A
- AVBP 2024
- Fundamental
- Price
- CTEV $38.50
- AVBP $18.66
- Analyst Decision
- CTEV Buy
- AVBP Strong Buy
- Analyst Count
- CTEV 1
- AVBP 8
- Target Price
- CTEV $44.00
- AVBP $38.38
- AVG Volume (30 Days)
- CTEV 90.2K
- AVBP 239.9K
- Earning Date
- CTEV 08-06-2025
- AVBP 08-13-2025
- Dividend Yield
- CTEV N/A
- AVBP N/A
- EPS Growth
- CTEV N/A
- AVBP N/A
- EPS
- CTEV N/A
- AVBP N/A
- Revenue
- CTEV $927,446,000.00
- AVBP N/A
- Revenue This Year
- CTEV $2.40
- AVBP N/A
- Revenue Next Year
- CTEV $3.12
- AVBP N/A
- P/E Ratio
- CTEV N/A
- AVBP N/A
- Revenue Growth
- CTEV N/A
- AVBP N/A
- 52 Week Low
- CTEV $4.80
- AVBP $15.47
- 52 Week High
- CTEV $51.29
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- CTEV N/A
- AVBP 29.95
- Support Level
- CTEV N/A
- AVBP $21.10
- Resistance Level
- CTEV N/A
- AVBP $22.29
- Average True Range (ATR)
- CTEV 0.00
- AVBP 1.02
- MACD
- CTEV 0.00
- AVBP -0.29
- Stochastic Oscillator
- CTEV 0.00
- AVBP 2.38
About CTEV CLARITEV CORPORATION
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.